Treatment Pathways and Health Outcomes of German Patients with Chronic Graft-Versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation: A Retrospective Health Claims Data Analysis.
Journal
Drugs - real world outcomes
ISSN: 2199-1154
Titre abrégé: Drugs Real World Outcomes
Pays: Switzerland
ID NLM: 101658456
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
accepted:
06
06
2022
pubmed:
3
7
2022
medline:
3
7
2022
entrez:
2
7
2022
Statut:
ppublish
Résumé
Although chronic graft-versus-host-disease (cGvHD) is an important long-term complication after allogenic hematopoietic cell transplantation (allo-HCT) and is associated with increased healthcare resource utilization, real-world evidence is scarce. The aim of the study was to evaluate survival of patients with cGvHD in Germany and to analyze hospitalization and treatment patterns. Based on a German claims database with 4.9 million enrollees, a retrospective longitudinal analysis covering a 6-year period between 2013 and 2018 was conducted. Patients with allo-HCT in 2014 or 2015 (index date) and no record of transplantation or documentation of GvHD 365 days prior to index were included. Patients who subsequently developed a cGVHD were compared with those who did not develop a cGVHD within 3 years after index date. cGVHD cases were identified based on documented International Classification of Diseases, Tenth Revision (ICD-10) diagnosis and treatment algorithms. Since the onset of cGvHD is defined at 100 days after allo-HCT, only those alive beyond day 100 were considered in the survival analysis. Patients who did not survive the first 100 days after allo-HCT were censored to prevent a selection bias due to early mortality within patients without GvHD. Survival rates were plotted using the Kaplan-Meier estimator. The number of hospitalizations and average lengths of stay as well as treatment patterns were descriptively examined. Overall, 165 cGvHD patients were identified and compared with 43 patients without cGVHD. Short-term survival rates were better for patients with cGvHD; the 6-month survival probability was 95.8% for patients with cGVHD and 83.7% for patients without cGVHD. However, long-term survival was better in patients without GvHD; The 30-month survival probability was 65.5% for patients with cGVHD and 76.7% for patients without cGVHD. While overall 90% of cGvHD patients were hospitalized at least once, the share was only half for patients without GvHD (44%). 78.2% of patients with cGVHD received corticosteroids in combination with other predefined immunosuppressants. Findings from this study reveal a high disease burden associated with cGvHD. This underlines the high medical need for new interventional strategies to improve survival and morbidity after allo-HCT.
Sections du résumé
BACKGROUND
BACKGROUND
Although chronic graft-versus-host-disease (cGvHD) is an important long-term complication after allogenic hematopoietic cell transplantation (allo-HCT) and is associated with increased healthcare resource utilization, real-world evidence is scarce.
OBJECTIVES
OBJECTIVE
The aim of the study was to evaluate survival of patients with cGvHD in Germany and to analyze hospitalization and treatment patterns.
PATIENTS AND METHODS
METHODS
Based on a German claims database with 4.9 million enrollees, a retrospective longitudinal analysis covering a 6-year period between 2013 and 2018 was conducted. Patients with allo-HCT in 2014 or 2015 (index date) and no record of transplantation or documentation of GvHD 365 days prior to index were included. Patients who subsequently developed a cGVHD were compared with those who did not develop a cGVHD within 3 years after index date. cGVHD cases were identified based on documented International Classification of Diseases, Tenth Revision (ICD-10) diagnosis and treatment algorithms. Since the onset of cGvHD is defined at 100 days after allo-HCT, only those alive beyond day 100 were considered in the survival analysis. Patients who did not survive the first 100 days after allo-HCT were censored to prevent a selection bias due to early mortality within patients without GvHD. Survival rates were plotted using the Kaplan-Meier estimator. The number of hospitalizations and average lengths of stay as well as treatment patterns were descriptively examined.
RESULTS
RESULTS
Overall, 165 cGvHD patients were identified and compared with 43 patients without cGVHD. Short-term survival rates were better for patients with cGvHD; the 6-month survival probability was 95.8% for patients with cGVHD and 83.7% for patients without cGVHD. However, long-term survival was better in patients without GvHD; The 30-month survival probability was 65.5% for patients with cGVHD and 76.7% for patients without cGVHD. While overall 90% of cGvHD patients were hospitalized at least once, the share was only half for patients without GvHD (44%). 78.2% of patients with cGVHD received corticosteroids in combination with other predefined immunosuppressants.
CONCLUSION
CONCLUSIONS
Findings from this study reveal a high disease burden associated with cGvHD. This underlines the high medical need for new interventional strategies to improve survival and morbidity after allo-HCT.
Identifiants
pubmed: 35779205
doi: 10.1007/s40801-022-00320-8
pii: 10.1007/s40801-022-00320-8
pmc: PMC9712900
doi:
Types de publication
Journal Article
Langues
eng
Pagination
577-588Informations de copyright
© 2022. The Author(s).
Références
Gesundheitswesen. 2015 Feb;77(2):120-6
pubmed: 25622207
Rheumatol Ther. 2021 Mar;8(1):483-497
pubmed: 33611778
Pharmacoepidemiol Drug Saf. 2016 Jan;25(1):106-9
pubmed: 26530279
Biol Blood Marrow Transplant. 2011 Jan;17(1):1-17
pubmed: 20685255
Z Evid Fortbild Qual Gesundhwes. 2016 Dec;118-119:48-55
pubmed: 27987568
Clin Cancer Res. 2015 May 1;21(9):2020-8
pubmed: 25348512
Arthritis Care Res (Hoboken). 2022 Sep;74(9):1435-1443
pubmed: 33742791
Drugs Real World Outcomes. 2022 Dec;9(4):577-588
pubmed: 35779205
Biol Blood Marrow Transplant. 2014 Nov;20(11):1737-43
pubmed: 25017765
Blood. 2001 Mar 1;97(5):1219-26
pubmed: 11222363
Z Evid Fortbild Qual Gesundhwes. 2014;108(8-9):511-6
pubmed: 25523850
Biol Blood Marrow Transplant. 2002;8(1):47-56
pubmed: 11858190
Curr Med Res Opin. 2021 May;37(5):755-759
pubmed: 33615925
Ther Adv Hematol. 2018 Jan;9(1):21-46
pubmed: 29317998
Haematologica. 2011 Nov;96(11):1678-84
pubmed: 21791465
Biol Blood Marrow Transplant. 2003 Apr;9(4):215-33
pubmed: 12720215
Front Public Health. 2020 Sep 25;8:572470
pubmed: 33072711
Transplant Cell Ther. 2021 Jun;27(6):504.e1-504.e6
pubmed: 34158154